TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients

Infectious Agents and Cancer

Maria Lina Tornesello²  Franco M Buonaguro²  Gerardo Botti³  Simona Losito³  Francesco Izzo¹  Luigi Buonaguro²  Valeria Di Vuolo² 

[1] Hepato-biliary Surgery Department, National Cancer Institute, "Fond. Pascale", Naples, Italy;Molecular Biology and Viral Oncology and AIDS Ref. Centre, National Cancer Institute "Fond. Pascale", Naples, Italy;Department of Pathology, National Cancer Institute, "Fond. Pascale", Naples, Italy

关键词: hepatocellular carcinoma;    MDM2 SNP309;    TP53 codon 72;    Genetic Polymorphisms;   

Others  :  805359
DOI  :  10.1186/1750-9378-6-13

 received in 2011-01-31, accepted in 2011-08-15,  发布年份 2011

【 摘 要 】

Background

Single-nucleotide polymorphisms within TP53 gene (codon 72 exon 4, rs1042522, encoding either arginine or proline) and MDM2 promoter (SNP309; rs2279744), have been independently associated with increased risk of several cancer types. Few studies have analysed the role of these polymorphisms in the development of hepatocellular carcinoma.

Methods

Genotype distribution of TP53 codon 72 and MDM2 SNP309 in 61 viral hepatitis-related hepatocellular carcinoma cases and 122 blood samples (healthy controls) from Italian subjects were determined by PCR and restriction fragment length polymorphism (RFLP).

Results

Frequencies of TP53 codon 72 alleles were not significantly different between cases and controls. A significant increase of MDM2 SNP309 G/G and T/G genotypes were observed among hepatocellular carcinoma cases (Odds Ratio, OR = 3.56, 95% Confidence Limits, 95% CI = 1.3-9.7; and OR = 2.82, 95% CI = 1.3-6.4, respectively).

Conclusions

These results highlight a significant role of MDM2 SNP309 G allele as a susceptibility gene for the development of viral hepatitis-related hepatocellular carcinoma among Italian subjects.

【 授权许可】

   
2011 Di Vuolo et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 2. Int J Cancer 2010.
• [2]Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, et al.: Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis 2. Int J Cancer 2011, 128:176-184.
• [3]Okuda K, Fujimoto I, Hanai A, Urano Y: Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987, 47:4967-4972.
• [4]Deuffic S, Poynard T, Buffat L, Valleron AJ: Trends in primary liver cancer. Lancet 1998, 351:214-215.
• [5]Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC: Increase in primary liver cancer in the UK, 1979-94. Lancet 1997, 350:1142-1143.
• [6]El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
• [7]Chuang SC, La VC, Boffetta P: Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection 1. Cancer Lett 2009, 286:9-14.
• [8]Donato F, Gelatti U, Limina RM, Fattovich G: Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence 1. Oncogene 2006, 25:3756-3770.
• [9]Tsukuma H, Hiyama T, Oshima A, Sobue T, Fujimoto I, Kasugai H, et al.: A case-control study of hepatocellular carcinoma in Osaka, Japan. Int J Cancer 1990, 45:231-236.
• [10]Romeo R, Colombo M: The natural history of hepatocellular carcinoma. Toxicology 2002, 181-182:39-42.
• [11]Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, et al.: Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer 2008, 44:847-853.
• [12]Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987, 7:961-963.
• [13]Pietsch EC, Humbey O, Murphy ME: Polymorphisms in the p53 pathway. Oncogene 2006, 25:1602-1611.
• [14]Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al.: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
• [15]Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al.: Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006, 43:531-533.
• [16]Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, et al.: The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007, 15:110-114.
• [17]Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al.: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006, 66:5104-5110.
• [18]Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al.: MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection 1. Carcinogenesis 2008, 29:1192-1196.
• [19]Tornesello ML, Duraturo ML, Waddell KM, Biryahwaho B, Downing R, Balinandi S, et al.: Evaluating the role of human papillomaviruses in conjunctival neoplasia. Br J Cancer 2006, 94:446-449.
• [20]Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, et al.: TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology 2009, 77:328-334.
• [21]Tornesello ML, Buonaguro L, Cristillo M, Biryahwaho B, Downing R, Hatzakis A, et al.: MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers 2011, 16:42-50.
• [22]Hrstka R, Coates PJ, Vojtesek B: Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009, 13:440-453.
• [23]Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 2009, 9:95-107.
• [24]Bonds L, Baker P, Gup C, Shroyer KR: Immunohistochemical localization of cdc6 in squamous and glandular neoplasia of the uterine cervix. Arch Pathol Lab Med 2002, 126:1164-1168.
• [25]Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al.: Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006, 98:285-288.
• [26]Capasso M, Ayala F, Avvisati RA, Russo R, Gambale A, Mozzillo N, et al.: MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. J Hum Genet 2010.
• [27]Bonafe M, Olivieri F, Mari D, Baggio G, Mattace R, Berardelli M, et al.: P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am J Hum Genet 1999, 65:1782-1785.
• [28]Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al.: Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett 2004, 208:75-79.
• [29]Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM: Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 2003, 193:199-205.
• [30]Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El KL, Afifi R, et al.: The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 2007, 37:748-754.
• [31]Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF: p53 codon 72 polymorphism and liver cancer susceptibility: A meta-analysis of epidemiologic studies. World J Gastroenterol 2011, 17:1211-1218.
• [32]Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ: A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999, 29:697-702.
• [33]Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al.: MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006, 12:4867-4871.
• [34]Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ: Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 2009, 15:5592-5597.
• [35]Ezzikouri S, El Feydi AE, Afifi R, El KL, Benazzouz M, Hassar M, et al.: MDM2 SNP309T > G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev 2009, 32:380-385.
• [36]Akkiz H, Sumbul AT, Bayram S, Bekar A, Akgollu E: MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol 2010, 34:448-452.
• [37]Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ: Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol 2011.
• [38]Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, et al.: A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells 1. J Biol Chem 2005, 280:26776-26787.
• [39]Bond GL, Hu W, Levine A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005, 65:5481-5484.
• [40]Michael D, Oren M: The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003, 13:49-58.
• [41]Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, et al.: MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007, 13:4123-4129.
• [42]Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME: mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 2003, 23:462-472.
• [43]Gong GZ, Jiang YF, He Y, Lai LY, Zhu YH, Su XS: HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding. World J Gastroenterol 2004, 10:2223-2227.
• [44]Siavoshian S, Abraham JD, Kieny MP, Schuster C: HCV core, NS3, NS5A and NS5B proteins modulate cell proliferation independently from p53 expression in hepatocarcinoma cell lines. Arch Virol 2004, 149:323-336.
• [45]Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, et al.: HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002, 21:4801-4811.